Proteolix Announces the Appointment of John Scarlett, M.D., President and CEO
“I am pleased to join the outstanding team at Proteolix, whose efforts have resulted in the discovery of the company’s lead anticancer product, the proteasome inhibitor carfilzomib, for the treatment of multiple myeloma and other cancers,” said Dr. Scarlett. “In particular, I am excited by the opportunity to oversee the advancement of carfilzomib, which has shown compelling single agent activity in several Phase 2 trials in multiple myeloma, through the final stages of clinical testing and into commercialization.”
“I welcome Dr. Scarlett, whose extensive clinical and commercial experience will serve as an important asset to the company as carfilzomib advances through late-stage trials,” stated Dr. Molineaux. “Proteolix has been successful in discovering and developing several inhibitors that selectively target the proteasome in new ways, which has allowed us to develop effective therapies for the treatment of both cancer and autoimmune diseases. I am proud of the progress our team has achieved to date and look forward to our continued successes.”
On behalf of the Company’s Board of Directors, Chairman
Dr. Scarlett most recently served as the Chief Executive Officer of Tercica, Inc., a publicly-traded biotechnology company, which he co-founded in 2002. While there, he led the company through the approval and commercialization of Increlex(R) and the commercialization of Somatuline Depot(R). Tercica merged in late 2008 with Ipsen,
Contact information Investors: Media Inquiries: Matthew Ferguson BCC Partners Chief Financial Officer Karen L. Bergman or Michelle Corral 650-266-2825 650-575-1509 or 415-794-8662 email@example.com
SOURCE Proteolix, Inc.